XellSmart, a developer of stem cell treatment solutions, has raised nearly 100 million yuan ($15 million) in its pre-Series A round. In a separate development, ByteDance and Asia-focused private equity firm Hillhouse Capital have backed tech firm RiVAI in its Series A round.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
